Clinica Chimica Acta最新文献

{"title":"Metabolomics in the Diagnosis of Bacterial Infections","authors":"Somayeh Ahmadi ,&nbsp;Farzaneh Rafie Sedaghat ,&nbsp;Mohammad Yousef Memar ,&nbsp;Mina Yekani","doi":"10.1016/j.cca.2024.120020","DOIUrl":"10.1016/j.cca.2024.120020","url":null,"abstract":"<div><div>One of the essential factors in the appropriate treatment of infections is accurate and timely laboratory diagnosis. The correct diagnosis of infections plays a vital role in determining desirable therapy and controlling the spread of pathogens. Traditional methods of infection diagnosis are limited by several factors such as insufficient sensitivity and specificity, being time-consuming and laborious, having a low ability to distinguish infection from non-infectious inflammatory conditions and a low potential to predict treatment outcomes. Therefore, it is necessary to find innovative strategies for detecting specific biomarkers in order to diagnose infections. The rapid advancement of metabolomics makes it possible to determine the pattern of metabolite changes in the both of pathogen and the host during an infection. Metabolomics is a method used to assess the levels and type of metabolites in an organism. Metabolites are of low-molecular-weight compounds produced as a result of metabolic processes and pathways within cells. Metabolomics provides valuable data to detect accurate biomarkers of specific biochemical features directly related to certain phenotypes or conditions. This study aimed to review the applications and progress of metabolomics as a biomarker for the diagnosis of bacterial infections.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120020"},"PeriodicalIF":3.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An accurate measurement method for serum homocysteine measurement by ID-LC/MS/MS and the application of external quality assessment","authors":"Mo Wang ,&nbsp;Jie Shi ,&nbsp;Yichuan Song,&nbsp;Shunli Zhang,&nbsp;Rui Zhang","doi":"10.1016/j.cca.2024.120021","DOIUrl":"10.1016/j.cca.2024.120021","url":null,"abstract":"<div><h3>Background</h3><div>Serum homocysteine (Hcy) measurement accuracy is essential for detecting and diagnosing cardio-cerebrovascular illnesses. Although many different methods have been developed to determine the concentration of Hcy, those different assays showed nonequivalent results. This study aimed to develop an accurate and precise isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC/MS/MS) method for serum homocysteine (Hcy) and assign values for reference materials used in external quality assessment (EQA) programs.</div></div><div><h3>Methods</h3><div>Different concentrations of homocysteine calibration solutions were prepared with d4-Hcy as the internal standard. This method employed DTT to reduce protein-bound Hcy, followed by protein precipitation, and gradient elution on a Supelcosil LC-CN column for chromatographic separation, and multiple reaction monitor (MRM) mode with electrospray ionization (ESI) for mass spectrometric detection. After optimized ID-LC/MS/MS parameters, imprecision, trueness, the limit of quantification (LoQ), the limit of detection (LoD), and measurement uncertainty were evaluated to check the methodological performance. The established method was employed in assigning values to EQA samples, which were sent to 63 clinical laboratories in Beijing to measure Hcy.</div></div><div><h3>Results</h3><div>At 10.69,15.99, and 37.80 μmol/L levels, the present method demonstrated analytical imprecision of 0.57 %, 0.65 %, and 0.57 %, and recoveries of 99.67 % to 100.21 %, respectively. The bias between the target values of GBW (Guojia Biaozhun Wuzhi) were − 0.79 % to 0.62 %. The LoQ and LoD for Hcy were 0.36 nmol/L and 0.27 nmol/L. The method had an uncertainty (U 95 %) of 1.34 % to 1.48 %. For the three levels of EQA samples, the percentage of laboratories meeting the trueness evaluation criteria (±10 %) was 81.67 %, 83.33 %, and 71.67 % respectively.</div></div><div><h3>Conclusions</h3><div>With optimal method precision and trueness, the ID-LC/MS/MS method to measure serum Hcy can be used for value assignment of EQA samples, which can provide reliable data for monitoring the accuracy of clinical laboratory for Hcy measurement.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120021"},"PeriodicalIF":3.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening biomarkers for autism spectrum disorder using plasma proteomics combined with machine learning methods","authors":"Xiaoxiao Tang ,&nbsp;Xiaoqian Ran ,&nbsp;Zhiyuan Liang ,&nbsp;Hongbin Zhuang ,&nbsp;Xi Yan ,&nbsp;Chengyun Feng ,&nbsp;Ayesha Qureshi ,&nbsp;Yan Gao ,&nbsp;Liming Shen","doi":"10.1016/j.cca.2024.120018","DOIUrl":"10.1016/j.cca.2024.120018","url":null,"abstract":"<div><h3>Background and aims</h3><div>Autism spectrum disorder (ASD) is a common neurodevelopmental disorder in children. Early intervention is effective. Investigation of novel blood biomarkers of ASD facilitates early detection and intervention.</div></div><div><h3>Materials and Methods</h3><div>Sequential window acquisition of all theoretical spectra-mass spectrometry (SWATH-MS)-based proteomics technology and 30 DSM-V defined ASD cases versus age- and sex-matched controls were initially evaluated, and candidate biomarkers were screened using machine learning methods. Candidate biomarkers were validated by targeted proteomics multiple reaction monitoring (MRM) analysis using an independent group of 30 ASD cases vs. controls.</div></div><div><h3>Results</h3><div>Fifty-one differentially expressed proteins (DEPs) were identified by SWATH analysis. They were associated with the immune response, complements and coagulation cascade pathways, and apolipoprotein-related metabolic pathways. Machine learning analysis screened 10 proteins as biomarker combinations (TFRC, PPBP, APCS, ALDH1A1, CD5L, SPARC, FGG, SHBG, S100A9, and PF4V1). In the MRM analysis, four proteins (PPBP, APCS, FGG, and PF4V1) were significantly different between the groups, and their combination as a screening indicator showed high potential (AUC = 0.8087, 95 % confidence interval 0.6904–0.9252, <em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>Our study provides data that suggests that a few plasma proteins have potential use in screening for ASD.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120018"},"PeriodicalIF":3.2,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UPLC-Q-TOF/MS-based urine metabolomics for the diagnosis and staging of bladder cancer","authors":"Xingyu Shi ,&nbsp;Wenbin Zheng ,&nbsp;Binhong He ,&nbsp;Longhui Huang ,&nbsp;Qisheng Zhong ,&nbsp;Yunfan Yang ,&nbsp;Ting Zhou ,&nbsp;Yong Huang","doi":"10.1016/j.cca.2024.120022","DOIUrl":"10.1016/j.cca.2024.120022","url":null,"abstract":"<div><h3>Background</h3><div>Bladder cancer (BC) is a common malignant tumour of the urinary system. Currently, the gold standard for diagnosing BC is cystoscopy, but it is an invasive examination that can lead to a certain psychological burden on the patient. In this study, we aimed to identify non-invasive potential metabolic biomarkers that could improve the diagnostic accuracy of bladder cancer.</div></div><div><h3>Methods</h3><div>Urine from 30 healthy people and 50 BC patients, including 40 non-muscle-invasive bladder cancer (NMIBC) patients and 10 muscle-invasive bladder cancer (MIBC) patients, were analyzed by liquid chromatography coupled with mass spectrometry to identify potential diagnostic metabolites. Binary Logistic regression was used to construct biomarker panels. Correlation analysis and construction of compound-reaction-enzyme-gene network were also performed to explore the possible mechanisms of BC development.</div></div><div><h3>Results</h3><div>Twenty-six metabolites were identified for differentiating BC patients from healthy controls, and eight metabolites were identified for differentiating NMIBC patients form MIBC patients. The biomarker panel consisting of urate, 4-Androstene-3α, 17β-diol and 3-Indoxyl sulfate can distinguish well between BC patients and healthy controls, with an area under the ROC curve (AUC) value of 0.983. And the biomarker panel consisting of L-Octanoylcarnitine, γ-Glutamylleucine, and heptanoylcarnitine for distinguishing NMIBC patients from MIBC patients had an AUC value of 0.941.</div></div><div><h3>Conclusions</h3><div>The diagnostic capability of the biomarker panels are superior to that of any single potential biomarker. This panel significantly benefits bladder cancer diagnostics and reveals insight into bladder cancer pathogenesis.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120022"},"PeriodicalIF":3.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPLC-MS/MS method for simultaneous analysis of plasma 2-hydroxybutyrate and 2-hydroxyisobutyrate: Development and clinical significance","authors":"Beatrice Campi ,&nbsp;Valentina Vitelli ,&nbsp;Federica Saponaro ,&nbsp;Riccardo Zucchi ,&nbsp;Ele Ferrannini ,&nbsp;Alessandro Saba","doi":"10.1016/j.cca.2024.120023","DOIUrl":"10.1016/j.cca.2024.120023","url":null,"abstract":"<div><div>Recent studies have identified relationships between diabetes mellitus and short-chain fatty acids, including 2-hydroxybutyrate (2-HB) and 2-hydroxyisobutyrate (2-HiB); 2-HB has been associated to the early stages of insulin resistance, while 2-HiB with the risk and progression of complications of Type 1 diabetes. Their metabolism and pathophysiological role in humans are not fully clarified.</div><div>The possible association between 2-HB and 2-HiB and diabetes mellitus was investigated with a novel mass spectrometry-based assay, capable of discriminating plasma 2-HiB and 2-HB from their HB isomers. Accuracy and precision (RSD%) were always in the range 99–102% and 0.7–3.5%, respectively. The study involved samples from subjects with normal glucose tolerance (NGT) and Type 2 diabetes (T2D), originally included in a multicenter study investigating mechanisms involved in atherothrombosis.</div><div>NGT subjects exhibited concentrations of 2-HB and 2-HiB of 61 (36) and 3.1 (1.9) µmol/L, median (interquartile range), respectively, that were significantly lower than those of the T2D patients, whose values were 74 (4.0) and 3.8 (2.9) µmol/L, respectively. The pattern of association of these molecules with clinical and metabolic variables is partially different: both compounds were directly related to male sex, BMI, HbA_1c, and plasma glucose, 2-HiB also with age, systolic blood pressure, and HDL-cholesterol. Furthermore, they correlate with free fatty acids, glycerol, and triglyceride concentrations, but the latter correlation was negative for 2-HB and positive for 2-HiB.</div><div>Results confirmed the clinical significance of 2-HB and 2-HiB, in differential association with metabolic features of T2D.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120023"},"PeriodicalIF":3.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of expanded carrier screening in the preconception and prenatal population: A Chinese cohort study","authors":"Yan Xu ,&nbsp;Ming Li ,&nbsp;Renyi Hua ,&nbsp;Xu Han ,&nbsp;Yi Wu ,&nbsp;Yiyao Chen ,&nbsp;Xinrong Zhao ,&nbsp;Li Gao ,&nbsp;Niu Li ,&nbsp;Jian Wang ,&nbsp;Yanlin Wang ,&nbsp;Shuyuan Li","doi":"10.1016/j.cca.2024.120017","DOIUrl":"10.1016/j.cca.2024.120017","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the clinical utility of expanded carrier screening (ECS) in Chinese preconception and prenatal populations, focusing on carrier frequency and the impact on at-risk couples (ARCs).</div></div><div><h3>Methods</h3><div>Data from 6,298 Chinese individuals from 4,420 families who underwent a 149-gene ECS panel at a single center were analyzed. The prevalence of positive carriers and ARCs was determined, with follow-up on reproductive decisions and pregnancy outcomes for ARCs.</div></div><div><h3>Results</h3><div>Of the individuals screened, 2,673 (42.4 %) were carriers of at least one pathogenic or likely pathogenic variant, and 98 (2.22 %) ARCs were identified. <em>GJB2</em>-related deafness and Duchenne muscular dystrophy were the most common autosomal recessive (AR) and X-linked disorders. Screening the top 11 (gene carrier rate [GCR] ≥ 1/100), 22 (GCR ≥ 1/200), and 41 (GCR ≥ 1/331) AR genes could identify 53.5 %, 67.9 %, and 81.3 % of variants, respectively. The corresponding ratios for identified ARCs were 90.4 %, 94.0 %, and 100 %. Follow-up data from 80 ARCs indicated that 75.0 % (60/80) took significant action based on the ECS results. Additionally, four families (3.5 %, 4/115) were identified at risk for a second disease unrelated to their initial family monogenic history.</div></div><div><h3>Conclusions</h3><div>This study, representing the largest cohort of a moderate-sized ECS panel test in the Chinese population, demonstrates the clinical utility of ECS in both healthy individuals and those with a family history of monogenic disorders. The data obtained provide valuable insights for developing a Chinese-specific ECS panel. Tailored approaches are critical for wider adoption and successful routine application of ECS.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120017"},"PeriodicalIF":3.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human cystatin C in fibrotic diseases","authors":"Gilles Lalmanach ,&nbsp;Baptiste Rigoux ,&nbsp;Alexis David ,&nbsp;Mounia Tahri-Joutey ,&nbsp;Fabien Lecaille ,&nbsp;Sylvain Marchand-Adam ,&nbsp;Ahlame Saidi","doi":"10.1016/j.cca.2024.120016","DOIUrl":"10.1016/j.cca.2024.120016","url":null,"abstract":"<div><div>Human cystatin C (hCC), which has a pervasive distribution within body fluids and is ubiquitously expressed by numerous cells and tissues, is a highly potent extracellular inhibitor of cysteine proteases. Besides measurement of serum creatinine, which is the most widely used technique for appraising glomerular filtration rate (GFR), hCC has emerged as a relevant GFR biomarker, because its quantification in serum is less sensitive to interferences with factors such as age, muscle mass or diet. Moreover, there are growing body of evidence that hCC overexpression and/or oversecretion, which is primarily driven by TGF-β1, occur during fibrogenesis (cardiac, liver, oral, and lung fibrosis). Even though molecular mechanisms and signaling pathways governing the regulation of hCC remain to be deciphered more acutely, current data sustain that hCC expression relates to myofibrogenesis and that hCC could be a specific and valuable biomarker of fibrotic disease.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120016"},"PeriodicalIF":3.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosensors for autoimmune diseases","authors":"Omid Yeganeh ,&nbsp;Elaheh Dalir Abdolahinia ,&nbsp;Saeideh Razi Soofiyani ,&nbsp;Elnaz Faghfuri ,&nbsp;Abbas Shafie ,&nbsp;Yasamin Pahlavan","doi":"10.1016/j.cca.2024.119998","DOIUrl":"10.1016/j.cca.2024.119998","url":null,"abstract":"<div><div>Diagnosis of autoimmune diseases (ADs) is usually based on symptoms and laboratory tests that measure the occurrence of serological and genetic biomarkers such as peptides, autoantibodies, and complement proteins. Early detection of AD is essential to reduce the severity of symptoms and organ damage as a result of progressive disease. Biosensors are tools that convert biochemical signals produced by molecular elements into optical, electrical, and other physical signals for analysis. In recent years, peptides, antigens, aptamers, autoantibodies, and other biomolecules have provided suitable diagnostic features for development of biosensors in detecting and follow up the diagnoses and treatment of diseases. This study reviews the introducing of different biomarkers in ADs with the novel vision to use of biosensor technology for research and development in this regard. Therefore, this study has the required innovation for using biosensor technology with more attention to electrochemical based biosensors to developing, targeting and designing the easy applicable and available diagnostic and response to treatment products using key biomolecules for ADs. It will help readers to understand the research trends of biosensors in ADs and further advance the development of this paramount field.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 119998"},"PeriodicalIF":3.2,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A French multicenter analytical evaluation of the automated Lumipulse G sNfL blood assay (Fujirebio®) and its comparison to four other immunoassays for serum neurofilament light chain assessment in clinical settings","authors":"Etienne Mondésert ,&nbsp;Susanna Schraen-Maschke ,&nbsp;Isabelle Quadrio ,&nbsp;Olivier Bousiges ,&nbsp;Damien Bouvier ,&nbsp;Constance Delaby ,&nbsp;Aurélie Bedel ,&nbsp;Sylvain Lehmann ,&nbsp;Anthony Fourier","doi":"10.1016/j.cca.2024.120007","DOIUrl":"10.1016/j.cca.2024.120007","url":null,"abstract":"<div><h3>Objectives</h3><div>Measurement of serum neurofilament light chain (sNfL) protein is becoming a key biomarker for many neurological diseases. Several immunoassays have been developed to meet these clinical needs, revealing significant differences in terms of variability and results. Here, we propose a French multicenter comparison of 5 sNfL assays.</div></div><div><h3>Methods</h3><div>6 replicates of 3 pools with low (10 pg/mL), medium (30 pg/mL) and high (100 pg/mL) sNfL values and one replicate of 12 samples with growing sNfL values were analyzed by six independent French clinical laboratories. The analytical performances of the sNfL blood assay (Fujirebio®) on Lumipulse G were first evaluated then compared to four other immunoassays: NF-light V2 (Quanterix®) on SiMOA HD-X, Human NF-L (Biotechne®) on Ella, R-Plex Human Neurofilament L (MSD®) on Sector 2400; manual ELISA test using Uman Diagnostic/Quanterix®.</div></div><div><h3>Results</h3><div>Inter-center comparison of the Lumipulse blood assay revealed limited but significant differences in the mean sNfL values across low, medium, and high pools between each city (p &lt; 0.001) and between the two different batches used. Coefficients of variation of pools ranged from 2.0 to 16.9 %. Z-score of sNfL results of the 12 samples ranged from −1.70 to +1.71. Inter-technique comparison showed a systematic difference of sNfL values, with a overestimation of MSD and Ella over other tests. Nonetheless, results were all significantly correlated (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>The automated Lumipulse assay produced comparable sNfL values across laboratories; but further adjustments are needed to harmonize sNfL results. Biologists and physicians should be aware of the variability in results between different immunoassay suppliers.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120007"},"PeriodicalIF":3.2,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNAs in glioblastoma","authors":"Elham Ghadami ,&nbsp;Mahjoobeh Jafari ,&nbsp;Masoumeh Razipour ,&nbsp;Mohaddese Maghsudlu ,&nbsp;Mohsen Ghadami","doi":"10.1016/j.cca.2024.120003","DOIUrl":"10.1016/j.cca.2024.120003","url":null,"abstract":"<div><div>Glioblastoma multiforme (GBM) is the most malignant and common form of brain cancer in adults. The molecular mechanisms underlying GBM progression and resistance are complex and poorly understood. Circular RNAs (circRNAs) are a new class of non-coding RNAs<!--> <!-->formed by covalently closed loop<!--> <!-->structures with no free ends. Their circular structure makes them more stable than linear RNA and resistant to exonuclease degradation. In recent years, they have received significant attention due to their diverse functions in gene regulation and their association with various diseases, including cancer. Therefore, understanding the functions and applications of circRNAs is critical to developing targeted therapeutic interventions and advancing the field of glioblastoma cancer research. In this review, we summarized the main functions of circRNAs and their potential applications in the diagnosis, prognosis and targeted therapy of GBM.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120003"},"PeriodicalIF":3.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}